Group 1 - The company, Shengda Bio, has a range of vitamin products including biotin and folic acid [2] - For raw material supply, the company primarily procures folic acid production materials through purchasing methods [2] - The company adopts a centralized procurement model for bulk raw materials to ensure high quality and stability of supply [2]

Group 1: Market Dynamics - As of December 29, 2025, there were 24 new private placement projects in the last two weeks, a decrease of 2 projects compared to the previous period[5] - The approval rate for projects was 100%, with 10 projects approved by the review committee, a decrease of 17 projects from the previous period[19] - The number of projects in the normal review stage is 636, with 88 projects having received approval and registration, a decrease of 4 projects[5] Group 2: Fundraising and Investment Trends - The total fundraising amount for the 7 projects listed in the last two weeks reached 72.86 billion yuan, an increase of 364.92% compared to the previous period[33] - The average base discount rate for competitive projects increased to 11.81%, up by 2.01 percentage points[33] - The average premium rate for competitive projects was 8.31%, a decrease of 2.31 percentage points from the previous period[40] Group 3: Project Analysis - Lingyun Technology plans to raise up to 695 million yuan to acquire 100% of JAI, which has an estimated value of 103 million euros, reflecting a valuation increase rate of 680.15%[24][26] - Guangha Communication aims to raise up to 750 million yuan for the construction of a new generation intelligent scheduling system, with revenue growth exceeding 20% in 2024 and the first three quarters of 2025[27] Group 4: Market Risks - Risks include slower-than-expected review progress for private placements, fluctuations in secondary market stock prices, and changes in the pricing environment for private placements[5]

Group 1 - The core point of the article is that Shengda Bio has announced a change in its signing registered accountants to Chen Ping and Hu Jue [2]

证券代码：603079 证券简称：圣达生物 公告编号：2025-072 浙江圣达生物药业股份有限公司 1、基本信息 陈平，1999年成为中国注册会计师，2002年开始从事上市公司审计，2013 年开始在致同事务所执业；2025年开始为本公司提供审计服务；近三年签署或 复核上市公司审计报告1份，具备相应专业胜任能力。 胡桔，2019年成为中国注册会计师，2016年开始从事上市公司审计，2025 年开始在致同事务所执业，2025年开始为本公司提供审计服务，近三年签署或 复核上市公司审计报告1份，具备相应专业胜任能力。 2、诚信记录 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江圣达生物药业股份有限公司（以下简称"公司"）于2025年8月22日召 开第四届董事会第十九次会议、于2025年9月10日召开2025年第三次临时股东大 会，审议通过了《关于公司聘任2025年度审计机构的议案》，同意聘任致同会 计师事务所（特殊普通合伙）（以下简称"致同事务所"）为公司2025年度审 计机构，为公司提供 ...

证券代码：603079 证券简称：圣达生物 公告编号：2025-071 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行及拟履行的审议程序 浙江圣达生物药业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召 开第四届董事会第十八次会议和第四届监事会第十六次会议，审议通过了《关于 使用闲置募集资金进行现金管理的议案》，同意公司及子公司使用额度不超过人 民币 23,000.00 万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流 动性好、有保本约定、产品期限不超过 12 个月的银行等金融机构现金管理产品 （包括但不限于结构性存款、大额存单等）。在上述期限及额度内，资金可滚动 使用，并授权公司董事长最终审定并签署相关实施协议或者合同等文件。保荐机 构对此出具了明确的核查意见。 特别风险提示 尽管公司使用闲置募集资金进行现金管理购买的产品属于低风险投资品种， 总体风险可控，但金融市场受宏观经济的影响较大，不排除该项投资 ...

Group 1: Overseas News - US stock market has seen five consecutive days of gains, with the Dow Jones up 0.6%, Nasdaq up 0.22%, and S&P 500 up 0.32%. Major tech companies like Apple, Meta, Microsoft, and Amazon saw increases of up to 0.53%, while Tesla, Google A, and Nvidia experienced declines of up to 0.32% [1] - Nvidia denied reports of a $200 million acquisition of AI chip startup Groq, stating that only a licensing agreement for inference technology was reached [1] - Samsung and SK Hynix are reportedly raising HBM3E prices by nearly 20% for next year [1] - Sanofi plans to acquire US vaccine company Dynavax for $2.2 billion to enhance its adult vaccine portfolio [1] Group 2: Domestic Major Events - The People's Bank of China and eight other departments issued opinions to support the construction of the Western Land-Sea New Corridor, exploring cross-border payment trials for digital RMB with Singapore [2][5] Group 3: Market Strategy Insights - Everbright Securities noted that the Shanghai Composite Index has shown strong performance with six consecutive days of gains, indicating a recovery in market sentiment and potential continued inflow of funds, particularly favoring technology growth stocks [3] Group 4: Real Estate Policy Changes - Beijing's new real estate policy, effective December 24, 2025, includes four main aspects: relaxing social security requirements for non-Beijing residents, supporting multi-child families in housing needs, optimizing commercial loan interest rates, and lowering the down payment ratio for second homes [4][5] Group 5: Digital Currency Developments - The digital RMB aims to address inefficiencies and high costs in traditional cross-border payments, with optimistic projections for transaction volumes reaching 162.4 trillion yuan by 2030 [6]

Group 1 - On December 25, a total of 8 companies had their restricted shares unlocked, with a total unlock volume of 247 million shares, amounting to a market value of 6.273 billion yuan based on the latest closing price [1] - The companies with the highest unlock volumes were Mousse Co., Ltd., Shengda Biology, and Guangdong Hongda, with unlock shares of 222 million, 17.84 million, and 4.4287 million respectively [1] - In terms of unlock market value, Mousse Co., Ltd., Shengda Biology, and Guangdong Hongda led with market values of 5.721 billion yuan, 304 million yuan, and 182 million yuan respectively [1] Group 2 - The companies with the highest unlock ratios relative to their total share capital were Mousse Co., Ltd., Shengda Biology, and Keda Control, with unlock ratios of 50.92%, 9.44%, and 1.42% respectively [1]

Summary of Key Points Core Viewpoint - On December 25, a total of 8 companies had their restricted shares unlocked, with a total unlock volume of 247 million shares, amounting to a market value of 6.273 billion yuan based on the latest closing prices [1]. Group 1: Unlock Volume - The companies with the highest unlock volumes were Mousse Co., Ltd., Shengda Biology, and Guangdong Hongda, with unlock shares of 222 million, 17.84 million, and 4.4287 million respectively [1]. Group 2: Unlock Market Value - In terms of unlock market value, Mousse Co., Ltd., Shengda Biology, and Guangdong Hongda led the way, with unlock market values of 5.721 billion yuan, 304 million yuan, and 18.2 million yuan respectively [1]. Group 3: Unlock Ratio - Regarding the proportion of unlock shares to total share capital, Mousse Co., Ltd., Shengda Biology, and Keda Control had the highest unlock ratios, at 50.92%, 9.44%, and 1.42% respectively [1].

证券代码：603079 证券简称：圣达生物 公告编号：2025-070 | 收益 | 受托方 | 产品 | 产品 | 产品 | 收益 | 认购金额 | 赎回本金 | 金额 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 起息日 | 到期日 | 名称 | 类型 | 名称 | 期限 | 类型 | （万元） | （万元） | （万 | | 元） | | | | | | | | | | | 中 | 国 | 建 | 中国建 | 设 | 银 | 行 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 设银行 | 浙 | 江 | 分 | 结构 | 保本 | 2025年 | 2025年 | 股份有 | 行 | 单 | 位 | | | | | | 性存 | 68天 | 浮动 | 10月15 | 12月22 | 8,000.00 | 8,000.00 | 2 ...

Core Viewpoint - The company has approved the use of up to 230 million yuan of idle raised funds for cash management, indicating a strategic approach to optimize financial resources [1] Group 1: Fund Management - On October 14, the company utilized 80 million yuan of idle raised funds to purchase a customized structured deposit product from China Construction Bank's Zhejiang branch [1] - The structured deposit product matured on December 22, with the company recovering the principal of 80 million yuan along with an interest income of 286,200 yuan, which was returned to the raised funds account [1] - The returns from the investment were in line with expectations, showing no significant discrepancies [1]